Japan Technology Journal
SEE OTHER BRANDS

The best science and technology news from Japan

Japanese Scientists Achieve 3D Jawbone-Like Organoids

(MENAFN) In a significant scientific advancement, Japanese scientists have successfully produced the world’s first 3D jawbone-like organoids using human-induced pluripotent stem (iPS) cells, according to a news agency on Tuesday.

Once implanted into mice, these tiny organoids matured into fully developed bone tissue, signaling a promising step forward in the field of regenerative therapies.

The researchers, based at Kyoto University, anticipate that the approach demonstrated in their study could be used for regenerative treatments and pharmaceutical testing in the future.

Details of their research were shared in a digital issue of the global journal Nature Biomedical Engineering in July.

Generating a jawbone posed a unique challenge because its formation process is distinct from that of other bones in the human body.

Furthermore, there had previously been no adequate technology capable of mimicking the intricate network of bone cells that form the majority of the jawbone structure.

To overcome these obstacles, the scientists cultivated human iPS cells, encouraging them to form clusters of cells that would later differentiate into jawbone cells.

MENAFN20082025000045017167ID1109951100

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions